31 August 2025 in Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is a common respiratory virus that can cause severe disease, particularly in older adults and adults with underlying medical conditions. However, RSV infections often go underdiagnosed due to infrequent testing and assay sensitivity limitations. To better understand RSV epidemiology and disease burden, we investigated respiratory virus testing patterns and characteristics associated with RSV testing among United States (US) adults aged ≥ 50 years with acute respiratory illnesses (ARIs). Methods This was a retrospective study using Optum® electronic health records data from 2015 to 2023. Medically-attended ARIs were identified among adults aged ≥ 50 years; percentages of ARIs tested for RSV and other respiratory viruses were calculated and stratified by epidemiological year (EY) and most intensive care setting during the ARI episode. Patient, provider, and ARI characteristics associated with the likelihood of RSV testing were assessed using multivariable logistic regression models. Results Among 22,475,891 included ARIs, RSV testing occurred in 2.4% (n = 530,452) of episodes. RSV testing increased over time (1.3–5.9% from 2016–2017 to 2022–2023 EYs), though it remained markedly lower than influenza (5.8–15.1%; 2016–2017 to 2022–2023 EYs) and SARS-CoV-2 (5.8–22.6%; 2019–2020 to 2022–2023 EYs) testing. By most intensive level of care received, RSV testing from 2016–2023 was more frequent in inpatient (9.5–27.5%) and emergency department (ED; 1.4–17.9%) settings than the outpatient setting (0.3–1.4%). Among included covariates in adjusted analyses, most intensive care setting [ED: 9.3-fold, inpatient: 31.2-fold (versus outpatient)] and healthcare organization (0.02–13.8-fold) were most significantly associated with likelihood of RSV testing. Conclusion The likelihood of RSV testing varied significantly by most intensive care setting and healthcare organization. Despite increasing RSV testing over time, RSV remains infrequently tested among US adults. Under-detection of medically-attended RSV cases should be accounted for when estimating RSV disease burden and the potential impact of RSV prevention strategies. A Graphical Abstract is available for this article. Graphical Abstract
23 December 2025 in Clinical Infectious Diseases
Background: Acute respiratory illnesses (ARIs) can be severe in older adults and adults with chronic conditions. We compared long-term outcomes of United States patients aged ≥50 years with ≥1 hospitalized ARI due to respiratory syncytial virus (RSV-ARI cohort) versus controls without ARI (control cohort) and patients with ≥1 hospitalized influenza-ARI (influenza-ARI cohort). Methods: This retrospective study used 1 October 2015–30 June 2023 claims data to evaluate clinical outcomes across the three cohorts. The index date was defined as the start of an ARI episode. Cumulative incidence functions assessed risks of readmission, all-cause mortality, myocardial infarction (MI), asthma and chronic obstructive pulmonary disease (COPD) exacerbation, and hospitalization due to heart failure (HHF); adjusted risks were compared using multivariable regression models. Results: A total of 14 759, 77 468, and 73 795 patients were selected into the RSV-ARI, influenza-ARI, and control cohorts, respectively. The RSV-ARI cohort had a substantially higher adjusted risk of all-cause mortality than controls, with the highest adjusted hazard ratio (95% confidence interval) 0–30 days post-index (10.772 [9.190, 12.627]). MI risk followed a pattern similar to all-cause mortality. Adjusted risks of asthma exacerbation, COPD exacerbation, and HHF were significantly higher in the RSV-ARI cohort than controls, and similar between RSV-ARI and influenza-ARI cohorts. Conclusions: RSV-ARI had considerable long-term impact on clinical outcomes, with measurable increases in outcomes associated with RSV-ARI when compared with controls, and similar outcomes compared to influenza-ARI. These findings can inform RSV prevention efforts and support future research on the long-term impact of RSV.
14 September 2026 in Human Vaccines & Immunotherapeutics